EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Liquid Compared to Solid Oral Formulations of the Thyroid Hormone Receptor Agonist Elunetirom Under Fasted and Fed Conditions in Healthy Participants

Jason R Harris, Aernout D van Haarst iD, Jill Baccei, Bridgette Franey, Jason Everett, Kory George, Sabina Paglialunga iD, Kenneth Webster, Michelle Hillstrand, Chris Banfield, Thomas S Scanlan, Gudarz Davar

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70743 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Jason R Harris und 11 weiteren Autor:innen. Beteiligte Einrichtung: Autobahn Therapeutics, San Diego, California, USA. Hauptthemen laut MEDLINE: Fasting, Food-Drug Interactions, Receptors, Thyroid Hormone. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Autobahn Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elunetirom (ABX‐002) is a brain‐targeted, oral prodrug being developed for the adjunctive treatment of major depressive disorder and bipolar depression. The active moiety, LL‐340001, is a thyroid hormone receptor agonist with modest selectivity for beta over alpha thyroid hormone receptors. Upon entering the brain, the intended site of action, elunetirom is hydrolyzed by fatty acid amide hydrolase to LL‐340001. In this 3‐way randomized, crossover, bioequivalence study, the pharmacokinetics (PK) and safety of an oral liquid formulation used in early clinical development were compared with those of an oral solid formulation intended for later‐stage development and potential commercialization, under fasted and fed conditions. Healthy adult participants received single doses of elunetirom (45 μg) as a liquid formulation under fasted conditions and as a solid formulation under fasted conditions and 30 min after consumption of a high‐fat meal. Administration of the solid formulation under fasted conditions resulted in elunetirom and LL‐340001 exposures similar to those observed with the liquid formulation and is therefore considered to have comparative bioavailability. Food intake increased elunetirom total exposure (AUC) compared with the fasted state but did not affect maximum exposure ( C max ). In contrast, administration with food reduced LL‐340001 C max compared with the fasted state but did not affect AUC. Food intake delayed the time to reach C max ( T max ) for both elunetirom and LL‐340001. Elunetirom, administered orally as a liquid and as a solid formulation, was safe and well tolerated under fed and fasted conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FastingFood-Drug InteractionsReceptors, Thyroid HormoneAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveBiological AvailabilityCross-Over StudiesHealthy VolunteersProdrugsTherapeutic EquivalencyAcetamides

Stichwörter der Autor:innen

ABX‐002LL‐340001bioavailabilitybioequivalencebipolar depressionmajor depressive disorderprodrugthyromimetic

Substanzen

ProdrugsReceptors, Thyroid HormoneAcetamides

Autor:innen und Institutionen

  • Autobahn Therapeutics, San Diego, California, USA.
  • Celerion, Lincoln, Nebraska, USA.
  • CB Pharma Consulting Services LLC, Cambridge, Massachusetts, USA.
  • Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: Aernout D van Haarst, Sabina Paglialunga

Förderung

  • Autobahn Therapeutics

Zitieren

APA

Harris, J. R., van Haarst, A. D., Baccei, J., Franey, B., Everett, J., George, K., Paglialunga, S., Webster, K., Hillstrand, M., Banfield, C., Scanlan, T. S., & Davar, G. (2026). Liquid Compared to Solid Oral Formulations of the Thyroid Hormone Receptor Agonist Elunetirom Under Fasted and Fed Conditions in Healthy Participants. Clinical and Translational Science. https://doi.org/10.1111/cts.70743

Vancouver

Harris JR, van Haarst AD, Baccei J, Franey B, Everett J, George K, et al. Liquid Compared to Solid Oral Formulations of the Thyroid Hormone Receptor Agonist Elunetirom Under Fasted and Fed Conditions in Healthy Participants. Clinical and Translational Science. 2026. doi:10.1111/cts.70743

BibTeX
@article{Harris2026,
  author = {Harris, Jason R and van Haarst, Aernout D and Baccei, Jill and Franey, Bridgette and Everett, Jason and George, Kory and Paglialunga, Sabina and Webster, Kenneth and Hillstrand, Michelle and Banfield, Chris and Scanlan, Thomas S and Davar, Gudarz},
  title = {Liquid Compared to Solid Oral Formulations of the Thyroid Hormone Receptor Agonist Elunetirom Under Fasted and Fed Conditions in Healthy Participants},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70743}
}
Kostenlos starten →